Jean Lu
YOU?
Author Swipe
View article: MEK1/2 inhibition prevents DENV and ZIKV infection via disrupting the cytoskeletal vimentin cage required for viral replication
MEK1/2 inhibition prevents DENV and ZIKV infection via disrupting the cytoskeletal vimentin cage required for viral replication Open
Flaviviridae Dengue virus (DENV) and Zika virus (ZIKV) have posed significant threats to global public health in the past decades. Despite extensive study on therapeutic strategies against these viruses, effective treatment options are sti…
View article: BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53
BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53 Open
Introduction: The Casein Kinase 1α (CK1α) gene resides on chromosome 5q and has haploid status in del5q MDS (Myelodysplastic Syndrome). Lenalidomide is a weak, but significant degrader of CK1α, and has clinical efficacy in del5q MDS relati…
View article: Supplementary Figure 5 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling
Supplementary Figure 5 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling Open
PDF file - 255K, The role of ABC transporters in cisplatin-induced multi-drug resistance to paclitaxol in H460 and H661 cell lines
View article: Supplementary Figure 3 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling
Supplementary Figure 3 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling Open
PDF file - 289K, Carboplatin induced DNA damage and CD133+ cell enrichment
View article: Supplementary Figure 2 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling
Supplementary Figure 2 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling Open
PDF file - 287K, Cisplatin-induced enrichment of CD133+ cells
View article: Data from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling
Data from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling Open
Platinum-based chemotherapy is the first-line treatment for non–small cell lung cancer, but recurrence occurs in most patients. Recent evidence suggests that CD133+ cells are the cause of drug resistance and tumor recurrence. However, the …
View article: Supplementary Figure 6 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling
Supplementary Figure 6 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling Open
PDF file - 342K, Inhibition of cisplatin-induced enrichment of CD133+ cells by Notch1 knockdown
View article: Supplementary Methods from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling
Supplementary Methods from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling Open
PDF file - 143K
View article: Supplementary Figure 4 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling
Supplementary Figure 4 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling Open
PDF file - 139K, Enrichment of ALDH+ cells by cisplatin treatment
View article: Supplementary Figure 1 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling
Supplementary Figure 1 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling Open
PDF file - 2.1MB, Cell differentiation and migration of GFP+ cells isolated from H460 cell line
View article: Supplementary Figure 1 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling
Supplementary Figure 1 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling Open
PDF file - 2.1MB, Cell differentiation and migration of GFP+ cells isolated from H460 cell line
View article: Supplementary Figure 4 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling
Supplementary Figure 4 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling Open
PDF file - 139K, Enrichment of ALDH+ cells by cisplatin treatment
View article: Supplementary Figure 6 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling
Supplementary Figure 6 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling Open
PDF file - 342K, Inhibition of cisplatin-induced enrichment of CD133+ cells by Notch1 knockdown
View article: Supplementary Figure 7 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling
Supplementary Figure 7 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling Open
PDF file - 138K, The role of Notch signaling in enrichment of CD133+ cells and multi-drug resistance of H661 cells
View article: Supplementary Figure 2 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling
Supplementary Figure 2 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling Open
PDF file - 287K, Cisplatin-induced enrichment of CD133+ cells
View article: Supplementary Methods from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling
Supplementary Methods from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling Open
PDF file - 143K
View article: Data from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling
Data from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling Open
Platinum-based chemotherapy is the first-line treatment for non–small cell lung cancer, but recurrence occurs in most patients. Recent evidence suggests that CD133+ cells are the cause of drug resistance and tumor recurrence. However, the …
View article: Supplementary Figure 7 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling
Supplementary Figure 7 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling Open
PDF file - 138K, The role of Notch signaling in enrichment of CD133+ cells and multi-drug resistance of H661 cells
View article: Supplementary Figure 5 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling
Supplementary Figure 5 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling Open
PDF file - 255K, The role of ABC transporters in cisplatin-induced multi-drug resistance to paclitaxol in H460 and H661 cell lines
View article: Supplementary Figure 3 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling
Supplementary Figure 3 from Cisplatin Selects for Multidrug-Resistant CD133<sup>+</sup> Cells in Lung Adenocarcinoma by Activating Notch Signaling Open
PDF file - 289K, Carboplatin induced DNA damage and CD133+ cell enrichment
View article: Podocalyxin‐Like Protein 1 Regulates Pluripotency through the Cholesterol Biosynthesis Pathway
Podocalyxin‐Like Protein 1 Regulates Pluripotency through the Cholesterol Biosynthesis Pathway Open
Deciphering signaling mechanisms critical for the extended pluripotent stem cell (EPSC) state and primed pluripotency is necessary for understanding embryonic development. Here, a membrane protein, podocalyxin‐like protein 1 (PODXL) as bei…
View article: Autologous Platelet-Rich Growth Factor Reduces M1 Macrophages and Modulates Inflammatory Microenvironments to Promote Sciatic Nerve Regeneration
Autologous Platelet-Rich Growth Factor Reduces M1 Macrophages and Modulates Inflammatory Microenvironments to Promote Sciatic Nerve Regeneration Open
The failure of peripheral nerve regeneration is often associated with the inability to generate a permissive molecular and cellular microenvironment for nerve repair. Autologous therapies, such as platelet-rich plasma (PRP) or its derivati…
View article: Development of a Chemical Cocktail That Rescues Mouse Brain Demyelination in a Cuprizone-Induced Model
Development of a Chemical Cocktail That Rescues Mouse Brain Demyelination in a Cuprizone-Induced Model Open
Oligodendrocytes are glial cells located in the central nervous system (CNS) that play essential roles in the transmission of nerve signals and in the neuroprotection of myelinated neurons. The dysfunction or loss of oligodendrocytes leads…
View article: A Randomized Crossover Trial Comparing Glucose Control During Moderate-Intensity, High-Intensity, and Resistance Exercise With Hybrid Closed-Loop Insulin Delivery While Profiling Potential Additional Signals in Adults With Type 1 Diabetes
A Randomized Crossover Trial Comparing Glucose Control During Moderate-Intensity, High-Intensity, and Resistance Exercise With Hybrid Closed-Loop Insulin Delivery While Profiling Potential Additional Signals in Adults With Type 1 Diabetes Open
Objective: To compare glucose control with hybrid closed loop (HCL) when challenged by moderate-intensity exercise (MIE), high-intensity intermittent exercise (HIE) and resistance exercise (RE) while profiling counter-regulatory hormones, …
View article: A Randomized Crossover Trial Comparing Glucose Control During Moderate-Intensity, High-Intensity, and Resistance Exercise With Hybrid Closed-Loop Insulin Delivery While Profiling Potential Additional Signals in Adults With Type 1 Diabetes
A Randomized Crossover Trial Comparing Glucose Control During Moderate-Intensity, High-Intensity, and Resistance Exercise With Hybrid Closed-Loop Insulin Delivery While Profiling Potential Additional Signals in Adults With Type 1 Diabetes Open
Objective: To compare glucose control with hybrid closed loop (HCL) when challenged by moderate-intensity exercise (MIE), high-intensity intermittent exercise (HIE) and resistance exercise (RE) while profiling counter-regulatory hormones, …
View article: Comparative Analyses of Single-Cell Transcriptomic Profiles between In Vitro Totipotent Blastomere-like Cells and In Vivo Early Mouse Embryonic Cells
Comparative Analyses of Single-Cell Transcriptomic Profiles between In Vitro Totipotent Blastomere-like Cells and In Vivo Early Mouse Embryonic Cells Open
The developmental potential within pluripotent cells in the canonical model is restricted to embryonic tissues, whereas totipotent cells can differentiate into both embryonic and extraembryonic tissues. Currently, the ability to culture in…
View article: Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System in Adults With Type 1 Diabetes: A Randomized, Open-Label, Crossover Trial
Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System in Adults With Type 1 Diabetes: A Randomized, Open-Label, Crossover Trial Open
Objective To evaluate glucose control using fast-acting insulin aspart (faster aspart) compared with insulin aspart (IAsp) delivered by the MiniMedä Advanced Hybrid Closed-Loop (AHCL) system in adults with type 1 diabetes. Research Design…